Background and Aims: The objective of this study was to examine the modulating effect of an appendectomy on the disease course of therapy-refractory ulcerative colitis [UC] patients, and to analyse appendiceal pathological characteristics predictive of pathological response. Methods: Patients with therapy-refractory UC, and referred for proctocolectomy, were invited to undergo laparoscopic appendectomy first. The primary end points were clinical response after 3 and 12 months. Secondary end points were endoscopic remission, failure, and pathologic response. Appendiceal specimens, and pre-and post-operative biopsies were histologically graded according to the validated Geboes score. Conclusions: Appendectomy was effective in one-third of therapy-refractory UC patients, with a substantial proportion of patients demonstrating complete endoscopic remission after 1 year. Pathological response was seen in almost 50% of patients and was related to active inflammation in the appendix, limited disease, and shorter disease duration. These early results suggest that there is a UC patient group that may benefit from appendectomy.
Introduction
Up to 30% of patients with ulcerative colitis [UC] ultimately require surgery. 1, 2 These patients have been extensively treated medically [often including trial medication], and are refractory to biologics or steroid dependent. Optimizing medical treatment for inflammatory bowel disease results in a decreased risk of surgery over the years, but this effect is most pronounced in Crohn's disease [CD] . 3 Therapy-refractory UC patients are often in a deplorable condition, unfit for immediate restorative proctocolectomy. The surgical treatment of choice is a colectomy with end-ileostomy first, followed by completion proctectomy with ileal J-pouch anastomosis at a later stage. 4 Although the postoperative outcomes are satisfactory, it involves at least two major abdominal surgeries, and a major change in bowel habits.
Various studies have evaluated the effect of a laparoscopic appendectomy as a therapeutic option in UC patients. A recent systematic review identified six observational studies evaluating the effect of an appendectomy in patients with established disease. The majority of studies demonstrated a beneficial effect in terms of reducing the need for immunosuppressants, reducing the relapse rate, or even reducing the colectomy rate in the long term. 5 The largest case series, by Bolin et al., of 30 ulcerative proctitis patients who underwent appendectomy, demonstrated a significant improvement in Simple Clinical Colitis Activity Index [SCCAI] in 90% of the patients, of which 40% were able to withdrawal all pharmacological treatments. 6 Although the pathogenesis of UC remains unresolved, it is often speculated that the defective mucosal barrier function and cytokine imbalance play an important role in the etiology of the disease. Penetration of luminal bacteria through the mucosal wall may cause an aberrant interaction with innate immune cells, causing an inflammatory response. One of the theories that has been proposed for linking the appendix to UC is that the appendix, with its inner layer of mucus and secretory IgA [called biofilm] functions as a reservoir for commensal bacteria. These bacteria can be secreted into the colon, influencing the microbiome and the immunological response. In this sense, an appendectomy may prevent recolonization of the gut, leading to a milder disease course. Another theory is that the cytokine production within the appendix may trigger an immunological cascade in the colon and rectum, causing inflammation, which may be prevented by an appendectomy. 7, 8 If a relatively safe and simple appendectomy could postpone or even prevent colectomy in therapy-refractory UC patients, this will result in enormous advantages for these patients, with a substantial gain in health and reduction in costs. The objective of this study was to examine the effect of an appendectomy to modulate the disease course of therapy-refractory UC, and analyse appendiceal pathological characteristics predictive of clinical response.
Methods

Study design
This prospective pilot study was conducted in two tertiary IBD centers [Academic Medical Center, Amsterdam, the Netherlands, and St Vincent's Hospital, Dublin, Ireland] between August 2012 and December 2015. Patients over 18 years of age with therapy-refractory or steroid-dependent UC requiring colectomy, despite complete medical treatment, were counselled to undergo compassionate-use laparoscopic appendectomy first. Patients were considered therapy refractory when 5-acetylsalicylic acid , corticosteroids, immunomodulators, and biologics [FDA-approved] had been attempted with minimal to no results. Each patient was thoroughly discussed at a multidisciplinary team [MDT] meeting, during which indication for colectomy and inclusion for the study was discussed by IBD gastroenterologists and surgeons. Patients were excluded from the study if they had undergone a prior appendectomy, other abdominal surgery, or if the MDT considered enhancement of medical therapy still appropriate. Other exclusion criteria were suspicion of CD; toxic mega-colon or other emergent surgical indication; active extra-intestinal infections; liver or kidney failure; and major lung and heart co-morbidity. Patients with insufficient knowledge of Dutch or English or who were cognitively unable to complete questionnaires were also excluded from the study.
Patients underwent ileocolonoscopy before appendectomy, after 3 months, and after 12 months, to assess disease activity and mucosal appearance. Biopsies were taken when possible. Patients signed an informed consent form approved by the institutional review board.
Surgical procedure
Laparoscopic appendectomy was performed within the first 6 weeks after inclusion. All appendectomies were performed by or under supervision of a dedicated IBD surgeon in a day-surgery setting. Care was taken not to touch the appendix during the surgical procedure to avoid disturbance of the microscopic findings. The appendix and caecal base were resected using a laparoscopic endostapler [enabling a safe and complete resection], including the orifice of the appendix with the possible peri-appendicular red patch [PARP] , also called a caecal patch. The resection specimen was handled according to a standard operating procedure and used for histological and immunohistochemical evaluation. Patients continued their medical treatment as given pre-appendectomy during the study period. After 3 months, patients were evaluated clinically and endoscopically, and in the case of response, medication was tapered.
Outcome measures
Results were measured by the Mayo score, which is the most commonly used activity score for UC. The total Mayo score is composed of four categories; three non-invasive clinical categories [bleeding, stool frequency, physician assessment] and one objective category [endoscopic appearance]. Each category is rated from 0 to 3, yielding a total score ranging from 0 to 12. 9 In this study, we evaluated the [partial] clinical Mayo score and the endoscopic Mayo score separately. The primary end points were the clinical Mayo score after 3 and 12 months. Secondary end points were endoscopic remission, failure, and pathological response. Clinical response was defined as a decrease in the clinical Mayo score of ≥3 points. Remission was defined as an endoscopic Mayo score of ≤1 point. Failure was defined as patients undergoing colectomy or starting trial medication.
Pathologic assessment
Pre-and post-operative biopsies [or appendiceal resection specimens in the case of failure] were histologically graded according to the Geboes score [0-5]. The Geboes score is a validated pathology score for UC and subdivides cases into six grades based on structural [architectural] change: no abnormality, chronic inflammatory infiltrate [architectural changes], lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction, and erosions or ulcerations. 10 Pathological response, defined as any decrease in the colonic Geboes score postoperatively, was correlated to clinical response. Although the Geboes score has been developed to grade colonic inflammation in UC, this score was also used to grade appendicular resection specimens in this study. Since it has been previously demonstrated that appendices in UC often show mucosal inflammation with comparable characteristics, this score was considered most appropriate for inventorying inflammatory changes. 12 To correlate appendicular findings to pre-and postoperative colonic pathological results, the IgA:IgG ratio was determined. No major postoperative complications occurred. One patient had an itchy skin rash after anaesthesia, which resolved after one day. Another patient needed additional pain medication due to abdominal tenderness.
Immunohistochemistry
Statistical analysis
Clinical and endoscopic response
Three months after surgery, five patients failed the study due to the requirement of colectomy [3 patients] Twelve months after appendectomy, an additional 6 patients had failed [4 due to colectomy, 2 due to start of trial medication]. Of the remaining 18 patients, 12 [30%] showed clinical response at this time point; 5 of these 12 were in endoscopic remission [ Figure 1] . None of the patients were using steroids at this time point. Microscopic analysis of the appendiceal resection specimen showed no microscopic characteristics of inflammation in two patients [Geboes 0 
Pathologic response
Immunohistochemistry
Immunohistochemistry of the resected appendices showed increased mucosal infiltration of CD4+ T-lymphocytes in the majority of appendices [ The results of the appendiceal IgA:IgG ratio in these therapyrefractory patients were more heterogeneous: the majority of appendiceal specimens showed ratios varying from 1:1-4:1, but there was also one appendix with a predominance of IgG-positive plasma cells [ratio 1 :6] . In general, the ratio in the appendix was lower when compared with that in the colon, with a trend towards a more normal [higher] ratio in the non-inflamed appendices [control appendices from FAP patients showing a ratio of 4:1, control colonic biopsies 8:1, data not shown]. A decrease in colonic inflammation after appendectomy was accompanied by an increase in the IgA:IgG ratio in the colon. This increase was not reflected by an absolute increase in IgA plasma cells, but was rather the result of a shift in the percentage of positive cells [ Figure 3 ].
Discussion
This study demonstrates that the appendix does play a role in UC, and that an appendectomy could be beneficial in therapy-refractory UC patients. After 3 months, over 50% of patients had a clinical response, which decreased to 30% after one year, with a substantial proportion of patients demonstrating complete endoscopic remission. Considering the fact that this patient group was referred for proctocolectomy, failing all regular medical treatments including biologics, these results seems promising. For the current study, the pathological response was of particular interest. Improvement in colonic pathology was seen in almost 50% of patients, which was predominantly related to active inflammation in the appendix. Previously, it has been demonstrated that the non-transmural mucosal appendicitis frequently seen in UC patients can be demonstrated by CD4 T-lymphocyte influx. This study confirmed this previous finding, but also demonstrated that the Geboes score, which is normally used to classify colonic inflammation, can be used to characterize appendiceal inflammation, and predict pathological colonic response.
In clinical practice, it would be of great value if appendiceal inflammation could be assessed during colonoscopy, predicting the modulating response of appendicectomy. In this context, the endoscopic finding of a caecal patch at the appendix orifice could be interesting. Unfortunately, in the current series the presence of this finding was not consistently scored preoperatively. In the literature, this PARP has been described in UC, and is generally considered to be a distinct 'skip lesion'. A recent review by Park et al. summarized all studies published until May 2012 regarding the role of a caecal patch in UC. Thirteen studies evaluated endoscopic reports and demonstrated a prevalence varying from 10 to 75%, but the clinical significance remained controversial, with the majority of studies describing a comparable disease course in patients with and without a caecal patch. 13 This review also reports that the patch is predominantly seen in patients with distal colitis, and it is tempting to speculate that the current finding, that patients with distal colitis have improved pathological response, could be related to the presence of a caecal patch.
The fact that a pathological response was more frequently seen in patients with distal colitis, when compared with patients with pancolitis, is also in line with the results from the only other prospective series analysing the effect of appendectomy for severe proctitis. 6 Although in this series a clinical response was seen in 90% of patients, it should be emphasized that this patient group only had moderate disease [Simple Clinical Colitis Activity Index 9, range 0-19] and a shorter disease duration [median 6 years], representing a patient group with a different prognostic profile. Interestingly, the current study also demonstrated that a pathologic response was more frequently seen in patients with shorter disease duration [median 5 years]. This finding suggests that patients with a longer disease course have more progressed, therapy-refractory disease. This is also in line with appendectomy findings in murine UC models, as well as large epidemiological studies that demonstrated a beneficial effect of an appendectomy at a younger age. 8, 14 The current study showed a pronounced discrepancy between how patients feel and what is seen during colonoscopy and pathology. It is not uncommon to find that clinical symptoms and endoscopic findings do not correlate. Two prospective studies of 101 UC patients in remission and 54 UC patients with varying disease severity demonstrated that serological markers [CRP and ESR] correlated well with the disease activity, but conflicting results were shown when comparing disease activity with endoscopic findings. 15, 16 In the current study, persistent clinical symptoms demanded colectomy in three patients, who had complete mucosal healing at pathological assessment. These patients insisted upon a colectomy after years of being unwell and not experiencing a clinical benefit from appendectomy in the short term.
One of the theories linking the appendix to UC is the fact that the appendix is a major site for generation of the IgA-secreting cells that migrate to the large intestine. In a mouse model, it was demonstrated that appendectomized mice show delayed and decreased accumulation of IgA + cells in the large intestine, resulting in an altered colonic faecal microbiota composition. 17 It has been suggested that this mechanism could be responsible for the beneficial effect of an appendectomy. However, these findings cannot be extrapolated to the human situation, as their results were the opposite to the present study. After an appendectomy, there was an increase in the amount of IgA, with an increasing ratio of IgA:IgG. As IgA is the most abundant class of antibodies found in the intestinal lumen of humans, this immune response has long been recognized as a first line of defense in protecting the intestinal epithelium from enteric pathogens and toxins. Restoring the normal ratio through an increase in IgA with a corresponding decrease in IgG, would therefore be beneficial, even though this probably should be considered as an indicator of disease activity, rather than a direct effect of the appendectomy. Since the appendix is generally considered the main source of secretory IgA [sIgA] production, we can hypothesize that an appendectomy may stimulate other gut-associated lymphoid tissues [GALT] to induce plasma cell production for sIgA, therefore causing an increased IgA:IgG ratio in the colon.
Recently two reports have emerged that suggest that an appendectomy does not prevent colectomy. 18, 19 In addition, an appendectomy could even be associated with an increased risk of high-grade dysplasia and cancer in the colon. As these are all retrospective series, the data are difficult to interpret, and there are too many confounding variables to draw firm conclusions. The indication for appendectomy in these patients is not described. It could be speculated that it was offered to patients who failed all medical treatment, or to patients with abdominal complaints mimicking appendicitis [representing perhaps a more severely affected group of UC patients]. When looking at the timing of colectomy, it is at least remarkable that the appendectomy group had a much longer duration of UC [151 vs 41 months], which could lead to speculation about a beneficiary effect of appendectomy, leading to a postponed colectomy, comparable with the results of this study. This could also explain the higher incidence of cancer found in the colectomy specimens after appendectomy. The cancer risk is predominantly increased in pancolitis patients after longer followup. Therefore, we do not think that this finding should lead to the conclusion that an appendectomy cannot be recommended for UC. However, one should be aware that this patient group with therapy-refractory disease is at risk of developing a malignancy, and careful follow-up and surveillance is mandatory. In line with these findings, a recent cohort study from the Swedish National Registry demonstrated in 63 711 UC patients that an appendectomy for appendicitis after established UC was associated with an increased rate of subsequent colectomy. In this study, the indication of colectomy was not reported, and therefore it is uncertain whether these patients also represent a more severely affected patient group, as mentioned before. Interestingly, this study demonstrated that appendectomy before the age of 20 years and before developing UC was associated with a lower risk of colectomy as well as UC-related hospital admissions. 20 The strength of our study is the prospective consecutive nature of the series, with the possibility of comparing pre-and postoperative biopsies. The weakness is the small number of patients, and the short follow-up. Studies analysing the effect of a new treatment strategy for UC often suffer from placebo effects of up to 30%. 21, 22 An invasive intervention like appendectomy in this patient group will definitely have some placebo effect, but in this study all clinical results were correlated to pathological responses, minimizing the likelihood of clinical improvement being due to the placebo effect. Long-term follow-up will have to be awaited to analyse whether there is a sustained benefit in these patients and whether an appendectomy can be implemented as a safe therapeutic option or as a bridge to proctocolectomy.
In conclusion, this study showed that appendectomy was clinically effective in at least 30% of therapy-refractory UC patients, with a substantial proportion of patients demonstrating complete endoscopic remission after 1 year. In addition, there was almost 50% pathological response. An appendectomy is a relatively simple procedure with low morbidity that can be performed in a daycare setting. Considering the fact that these patients otherwise had to sacrifice their colon, these results can be considered as suggesting a considerable benefit. Pathological response was related to active inflammation in the appendix, but there appears to be a discrepancy between clinical symptoms and what is seen during colonoscopy and pathology. In contrast, patients with pancolitis and longstanding disease duration were less likely to respond. These early results suggest that UC patients with mucosal appendicitis may benefit from appendectomy.
Funding
No financial interest/funding is applicable to any of the authors of this manuscript.
